Dawid L Staudacher1, Wolfgang Gold2, Paul M Biever2, Christoph Bode2, Tobias Wengenmayer2. 1. Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany. Electronic address: dawid.staudacher@universitaets-herzzentrum.de. 2. Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany.
Abstract
PURPOSE: For circulatory support, venoarterial extracorporeal membrane oxygenation (VA-ECMO) is dependent on sufficient venous drainage ensured by fluid therapy. Volume overload however is linked to poor prognosis. This study therefore evaluates volume therapy in VA-ECMO. MATERIAL AND METHODS: We report data of a single center registry of all patients after VA-ECMO implantation treated between 2010 and 2015. RESULTS: A total of 195 patients were included in this registry with a medium age of 58.2 ± 1.1 years, 71.8% were male. A positive fluid balance was detected in 94.7% at day 1 (day 2: 93.7%, day 3: 92.6%). Consistently, survivors had a lower fluid balance when compared to non-survivors (P < .001). Three hours post-implantation, patients above the 75th percentile had a hazard ratio of 6.03 when compared to average survival (P < .05). AUC at that time point was 0.726 as calculated by ROC. Patients below the 50th percentile (fluid balance below 8500 mL after 24 hours) had the best prognosis after VA-ECMO implantation (P < .001). CONCLUSIONS: Higher fluid balance was consistently linked to poor survival. We found no evidence to support a liberal fluid therapy in VA-ECMO patients, especially not the early after implantation. With a retrospective study, one cannot clarify if lower fluid balance might improve outcomes or represents a prognostic marker.
PURPOSE: For circulatory support, venoarterial extracorporeal membrane oxygenation (VA-ECMO) is dependent on sufficient venous drainage ensured by fluid therapy. Volume overload however is linked to poor prognosis. This study therefore evaluates volume therapy in VA-ECMO. MATERIAL AND METHODS: We report data of a single center registry of all patients after VA-ECMO implantation treated between 2010 and 2015. RESULTS: A total of 195 patients were included in this registry with a medium age of 58.2 ± 1.1 years, 71.8% were male. A positive fluid balance was detected in 94.7% at day 1 (day 2: 93.7%, day 3: 92.6%). Consistently, survivors had a lower fluid balance when compared to non-survivors (P < .001). Three hours post-implantation, patients above the 75th percentile had a hazard ratio of 6.03 when compared to average survival (P < .05). AUC at that time point was 0.726 as calculated by ROC. Patients below the 50th percentile (fluid balance below 8500 mL after 24 hours) had the best prognosis after VA-ECMO implantation (P < .001). CONCLUSIONS: Higher fluid balance was consistently linked to poor survival. We found no evidence to support a liberal fluid therapy in VA-ECMO patients, especially not the early after implantation. With a retrospective study, one cannot clarify if lower fluid balance might improve outcomes or represents a prognostic marker.
Authors: Tobias Wengenmayer; Florentine Schroth; Paul M Biever; Daniel Duerschmied; Christoph Benk; Georg Trummer; Klaus Kaier; Christoph Bode; Dawid L Staudacher Journal: Intensive Care Med Date: 2018-11-14 Impact factor: 17.440
Authors: Tobias Wengenmayer; Stephan Rombach; Florian Ramshorn; Paul Biever; Christoph Bode; Daniel Duerschmied; Dawid L Staudacher Journal: Crit Care Date: 2017-06-22 Impact factor: 9.097
Authors: Jonathan Rilinger; Viviane Zotzmann; Xavier Bemtgen; Carin Schumacher; Paul M Biever; Daniel Duerschmied; Klaus Kaier; Peter Stachon; Constantin von Zur Mühlen; Manfred Zehender; Christoph Bode; Dawid L Staudacher; Tobias Wengenmayer Journal: Crit Care Date: 2020-07-08 Impact factor: 9.097
Authors: D Duerschmied; V Zotzmann; M Rieder; X Bemtgen; P M Biever; K Kaier; G Trummer; C Benk; H J Busch; C Bode; T Wengenmayer; P Stachon; C von Zur Mühlen; D L Staudacher Journal: Sci Rep Date: 2020-05-21 Impact factor: 4.379
Authors: Jonathan Rilinger; Viviane Zotzmann; Xavier Bemtgen; Siegbert Rieg; Paul M Biever; Daniel Duerschmied; Torben Pottgiesser; Klaus Kaier; Christoph Bode; Dawid L Staudacher; Tobias Wengenmayer Journal: Artif Organs Date: 2021-05-04 Impact factor: 2.663
Authors: Markus Jäckel; Jonathan Rilinger; Corinna Nadine Lang; Viviane Zotzmann; Klaus Kaier; Peter Stachon; Paul Marc Biever; Tobias Wengenmayer; Daniel Duerschmied; Christoph Bode; Dawid Leander Staudacher; Alexander Supady Journal: Artif Organs Date: 2020-12-18 Impact factor: 2.663